1. Home
  2. BRAI vs ADPT Comparison

BRAI vs ADPT Comparison

Compare BRAI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRAI

Braiin Limited Common Stock

N/A

Current Price

$7.51

Market Cap

2.6B

Sector

N/A

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$17.40

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRAI
ADPT
Founded
N/A
2009
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BRAI
ADPT
Price
$7.51
$17.40
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$17.78
AVG Volume (30 Days)
709.2K
3.3M
Earning Date
N/A
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
N/A
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$6.62
$9.96
52 Week High
$32.32
$20.76

Technical Indicators

Market Signals
Indicator
BRAI
ADPT
Relative Strength Index (RSI) 43.52 59.43
Support Level $6.72 $14.87
Resistance Level $18.59 $17.72
Average True Range (ATR) 1.44 1.35
MACD 0.23 0.01
Stochastic Oscillator 15.45 58.34

Price Performance

Historical Comparison
BRAI
ADPT

About BRAI Braiin Limited Common Stock

Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: